Navigation Links
Study highlights new and cheaper way to treat heroin addiction

Costly methadone treatment for heroin addicts could be replaced by a substitute painkiller that is half the price, safer and less toxic.

In a study spanning three and a half years, researchers found that the prescription painkiller dihydrocodeine is equally as effective as methadone to help drug users kick the habit.

The research by the Universities of Edinburgh, Napier and Adelaide could have major implications for treatment programmes for drug users, which have proved controversial not least because of the high costs involved.

In contrast to methadone –which comes in liquid not tablet form ?dihydrocodeine is much easier to store and comes under less stringent regulations because it is not as toxic and less likely to cause a fatal overdose. It is estimated that whereas methadone treatment can cost almost £1,500 annually per patient, the cost of dihydrocodeine is £713.

Dihydrocodeine has been used by GPs and specialists for many years to treat drug users . It is often preferred in situations where methadone is seen as hazardous, such as police custody or prison. Its effectiveness has, however, never been tested before.

Dr Roy Robertson, a Reader at the University of Edinburgh, who is the study’s main author, said: "Heroin addiction is a chronic condition requiring long-term medication. Just as with other chronic conditions, such as diabetes or arthritis, there should be a number of treatments available so that doctors and nurses can tailor medication to the needs of each patient.

"Methadone should still be used to treat the majority of patients withdrawing from heroin and requiring maintenance treatment, but dihydrocodeine offers an alternative treatment for those who can’t tolerate methadone, or find it hard to deal with the stigma of having to take their dose ?sometimes every day ?in a pharmacy. It is also much cheaper."

The study, the first of its kind in the world, assessed 235 people requiring
'"/>

Source:University of Edinburgh


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:11/4/2009).... 26 BIO-key Internation...inger-based biometric identification software is s...the AABB TXPO conference being held at the New Orl...O-key will provide hands-on product demonstrations... in booth #424. Also, at 5 PM on Monday, October 2...
(Date:11/3/2009)...BER 4, 2009 -- The world,s greatest wines are the..., human input, and something called the "terroir" ..., and climate. , Experts will discuss terroir ... Wednesday, Nov. 4 in Pittsburgh. "Terroir: Wineg...o parts at the 2009 Annual Meetings of the America...
(Date:11/3/2009)... Obese women are as much as 28 percent less likel...cy, according to research that earned a Michigan S...e findings by Barbara Luke, a researcher in the MS...rics, Gynecology and Reproductive Biology, focused...roductive technology. , Luke,s findings, which a...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Great wines come from great soils 2MSU researcher: Obesity significantly cuts odds of successful pregnancy 2Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 1Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 2Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 3China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 1China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 2Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 1Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 2Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 3Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 4Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 5
...for controlling a first key step in the creation o... the journal Nature tomorrow (Thursday 27 October ... early processes that take place once a sperm ente...ndamental process in sexually reproducing animals....ternal (mother,s) genome explains why eggs fail to...
...toxicological study on water-soluble buckyballs, r...cal and Environmental Nanotechnology (CBEN) find t...ly less toxic to begin with. Moreover, the researc...ndered nontoxic with minor chemical modifications....studies of water-soluble carbon nanotubes. The stu...
...ty of California, San Diego that appears in the Au...hat females of the species Uca crenulata may check...ows before finally deciding on a mate. , “As far a...ing nearly as many candidates as the California fi... the study while a doctoral student and a lecturer...
Other Biology News:Scientists unpick genetics of first 15 minutes of life 2Modifications render carbon nanotubes nontoxic 2Modifications render carbon nanotubes nontoxic 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 P...h is set to take place on February 22-24, 2010 in ...y conference we will highlight key issues in formi...are their experiences. , ...enda for Arrowhead’s 2010 Personalized Medi...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...Y, N.J., Nov. 5 DSM Pharmaceutical...acturing alliance with Galenix, Saint Jean D,Illac...al scale manufacturing partner for Galenix commerc...nix will collaborate on business development oppor...logies, based on the strength of Galenix in drug p...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...IA, Calif., April 28 MannKind,Corporation (Nasdaq...commercializing treatments for diabetes and cancer...an Stanley Healthcare Conference on Wednesday,Apri...Biscayne, Florida., Interested parties can access...n the Investor Relations section of the Company,s ...
...KNOLLS, N.J., April 28 Emisphere,Technologies, In...08 it,received a letter from the NASDAQ Stock Mark...st 10 consecutive trading days, the Company,s,mark...inimum $50,000,000,requirement for continued inclu...Q Marketplace Rule 4450(b)(1)(A). Furthermore, NAS...
...ND, Calif., April 28 Sangamo,BioSciences, Inc. (N...opment,of novel zinc finger DNA-binding proteins (...tion, announced today the nomination of Thomas G.,... Wiggans most recently served as Chief Executive O...ompany, from 1994, and as Chairman,of the Board fr...
Other Biology Technology:Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements 2Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4
GIBCO Streptomycin Sulfate from Invitrogen
GIBCO Dulbeccos Modified Eagle Medium (D-MEM) (1X); powder (low glucose) from Invitrogen
Goat Anti-Adducin beta (C-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
Biology Products: